Engineering
the Next
Era of
Immunotherapy
Engineering
the Next Era
of Immunotherapy
Multi-specific CAR-T cells
designed to outsmart
AML’s complexity.
Batazu Advanced Therapeutics is developing BAT-33/CLL1, a dual-target CAR T cell therapy for patients with Acute Myeloid Leukaemia (AML). By targeting both CD33 and CLL1, our approach aims to improve disease control in patients who relapse after standard treatments.
Dual-target precision
BAT-33/CLL1 recognises CD33 and CLL1 on AML cells, aiming to reduce antigen escape and improve depth of response.
Ultra-rapid manufacturing
We are building a hospital-compatible manufacturing process to shorten vein-to-vein time and better match the urgency of high-risk AML.
AML-focused
Our research and development strategy is dedicated to myeloid malignancies, with an initial focus on relapsed or refractory AML.
European collaboration
Batazu works with leading European hospitals, research institutes and partners to translate advanced cell therapies into clinical practice.
Redefining CAR-T for the
Hardest-to-Treat Leukemias
Pioneering multi-specific targeting to overcome resistance in AML.
Approach
BAT-33/CLL1 is designed
to overcome AML’s biological diversity.